About
Technology
Issues
FAQ
Title
Abstract
Text
Figure Captions
Table Cells
Section Titles
Keywords
Subjects
Authors
From
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1995
1990
1985
1980
1975
1970
1960
1950
1940
1930
1920
1910
1900
1850
1800
1700
1600
To
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1995
1990
1985
1980
1975
1970
1960
1950
1940
1930
1920
1910
1900
1850
1800
1700
1600
All Types
Articles
Communications
Reviews
Discussions
Case Reports
Order By
Order By Year ASC
Order By Year DESC
Order By Citations ASC
Order By Citations DESC
Go
Profile
Top Authors
Prolific Authors
Top Journals
Main Disciplines
Main Topics
Most Cited Articles
Scientometrics
Avg Impact Factor
★★
Articles
★★★
Articles
exaly
›
Institutions
›
Kanagawa Cancer Center
›
Department of Medical Oncology
›
Top Articles
Department of Medical Oncology
Kanagawa Cancer Center
517
Articles
12.1K
Citations
2.4
avg. Impact Factor
48
h-index
Most Cited Articles of Department of Medical Oncology in 2022
Title
Journal
Year
Citations
Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma.
New England Journal of Medicine
2022
30
Adjuvant S-1 versus observation in curatively resected biliary tract cancer: A phase III trial (JCOG1202: ASCOT).
Journal of Clinical Oncology
2022
3
Prevalence estimates of Helicobacter species infection in pancreatic and biliary tract cancers.
Helicobacter
2022
2
A phase II study of nivolumab in combination with modified FOLFIRINOX for metastatic pancreatic cancer.
Journal of Clinical Oncology
2022
2
Right ventricular overloading is attenuated in monocrotaline-induced pulmonary hypertension model rats with a disrupted Gpr143 gene, the gene that encodes the 3,4-l-dihydroxyphenyalanine (l-DOPA) receptor.
Journal of Pharmacological Sciences
2022
2
Assessment of the use of computed tomography colonography in early detection of peritoneal metastasis in patients with gastric cancer: A prospective cohort study.
PLoS ONE
2022
1
Phase II study of atezolizumab with bevacizumab for non-squamous non-small cell lung cancer with high PD-L1 expression (@Be Study).
2022
1
Identification of CT Values That Could Be Predictive of Necrosis (N-CTav) in Hepatocellular Carcinoma after Lenvatinib Treatment
Current Oncology
2022
1
Comparative Outcomes of First-Line Chemotherapy for Metastatic Pancreatic Cancer Among the Regimens Used in Japan: A Systematic Review and Network Meta-analysis.
JAMA Network Open
2022
0
The clinical outcomes of combination chemotherapy in elderly patients with advanced biliary tract cancer: an exploratory analysis of JCOG1113.
Scientific Reports
2022
0
Randomized multicenter phase II/III study of gemcitabine plus nab-paclitaxel or modified FOLFIRINOX or S-IROX in patients with metastatic or recurrent pancreatic cancer (JCOG1611, GENERATE).
Journal of Clinical Oncology
2022
0
Identification and quantitative structure-activity relationship assessment of trace chemical impurities contained in the therapeutic formulation of [Cu]Cu-ATSM.
Nuclear Medicine and Biology
2022
0
Impact of the KIT/PDGFRA genotype on prognosis in imatinib-naïve Japanese patients with gastrointestinal stromal tumor.
Annals of Gastroenterological Surgery
2022
0
Comprehensive geriatric assessment as a useful tool in predicting adverse events in elderly patients with diffuse large B-cell lymphoma.
Scientific Reports
2022
0
Clinical Validity of Plasma-Based Genotyping for Microsatellite Instability Assessment in Advanced GI Cancers: SCRUM-Japan GOZILA Substudy.
JCO Precision Oncology
2022
0
Authors' reply to the Letter to the Editor: Tissue factor and its procoagulant activity on cancer-associated thromboembolism in pancreatic cancer.
Cancer Science
2022
0
Upregulation of PODXL and ITGB1 in pancreatic cancer tissues preoperatively obtained by EUS-FNAB correlates with unfavorable prognosis of postoperative pancreatic cancer patients.
PLoS ONE
2022
0
Comparative study between sorafenib and lenvatinib as the first-line therapy in the sequential treatment of unresectable hepatocellular carcinoma in a real-world setting.
JGH Open
2022
0
Sarcopenia: Prognostic Value for Unresectable Pancreatic Ductal Adenocarcinoma Patients Treated With Gemcitabine Plus Nab-Paclitaxel.
Pancreas
2022
0
A prospective observational cohort study of lenvatinib as initial treatment in patients with BCLC-defined stage B hepatocellular carcinoma.
BMC Cancer
2022
0
Feasibility of adjuvant S-1 chemotherapy after major hepatectomy for biliary tract cancers: An exploratory subset analysis of JCOG1202.
Journal of Clinical Oncology
2022
Nal-IRI+5-FU/LV vs 5-FU/LV in metastatic pancreatic cancer: Additional safety report of randomized Japanese phase 2 trial.
Journal of Clinical Oncology
2022
The influence of major hepatectomy on gemcitabine-based chemotherapy for advanced biliary tract cancer: An exploratory subset analysis of JCOG1113.
Journal of Clinical Oncology
2022
A prospective observational study of lenvatinib as an initial treatment for patients with intermediate-stage hepatocellular carcinoma.
Journal of Clinical Oncology
2022
Successful treatment with brentuximab vedotine for a patient with very late relapse of limited stage classic Hodgkin lymphoma.
International Cancer Conference Journal
2022
Schools/Departments
The list of schools/departments is not comprehensive since it is common to drop the department in the affiliation.
site/software ©
exaly
; All materials licenced under
CC by-SA
.